FDA approves GSK lung cancer drug Jideytro ahead of schedule
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech results revive AI spending worries; oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Dollar hits fresh 40-year high versus yen, edges down against euro
- Oil prices rise for a fifth day as US-Iran hostilities threaten supply routes
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
July 22, 2026 1:59 PM EDTApproval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1Next-generation design aims to address key efficacy and tolerability challenges of treating ROS1-positive NSCLCGSK's first approval in lung cancer, part of a growing portfolio of targeted treatments
LONDON, July 22, 2026 /PRNewswire/ --... More
